175 related articles for article (PubMed ID: 16153395)
1. Individual and joint association of alpha1A-adrenergic receptor Arg347Cys polymorphism and plasma irbesartan concentration with blood pressure therapeutic response in Chinese hypertensive subjects.
Jiang S; Mao G; Zhang S; Hong X; Tang G; Li Z; Liu X; Zhang Y; Wang B; Xu X; Wang X
Clin Pharmacol Ther; 2005 Sep; 78(3):239-48. PubMed ID: 16153395
[TBL] [Abstract][Full Text] [Related]
2. Interactive effect of angiotensin II type 1 receptor (AGT1R) polymorphisms and plasma irbesartan concentration on antihypertensive therapeutic responses to irbesartan.
Jiang S; Hsu YH; Venners SA; Zhang Y; Xing H; Wang X; Xu X
J Hypertens; 2011 May; 29(5):890-5. PubMed ID: 21346624
[TBL] [Abstract][Full Text] [Related]
3. Association between human atrial natriuretic peptide Val7Met polymorphism and baseline blood pressure, plasma trough irbesartan concentrations, and the antihypertensive efficacy of irbesartan in rural Chinese patients with essential hypertension.
Zhang S; Mao G; Zhang Y; Tang G; Wen Y; Hong X; Jiang S; Yu Y; Xu X
Clin Ther; 2005 Nov; 27(11):1774-84. PubMed ID: 16368448
[TBL] [Abstract][Full Text] [Related]
4. Interactive Effect of the KCNJ11 Ile337Val Polymorphism and Cigarette Smoking on the Antihypertensive Response to Irbesartan in Chinese Hypertensive Patients.
Jiang S; Venners SA; Hsu YH; Weinstock J; Wang B; Xing H; Wang X; Xu X
Am J Hypertens; 2016 May; 29(5):553-9. PubMed ID: 26304961
[TBL] [Abstract][Full Text] [Related]
5. CYP2C9 Ile359Leu polymorphism, plasma irbesartan concentration and acute blood pressure reductions in response to irbesartan treatment in Chinese hypertensive patients.
Chen G; Jiang S; Mao G; Zhang S; Hong X; Tang G; Li Z; Liu X; Zhang Y; Xing H; Wang B; Yu Y; Xu X
Methods Find Exp Clin Pharmacol; 2006; 28(1):19-24. PubMed ID: 16541193
[TBL] [Abstract][Full Text] [Related]
6. The relationship between the plasma concentration of irbesartan and the antihypertensive response is disclosed by an angiotensin II type 1 receptor polymorphism: results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation vs. Atenolol (SILVHIA) Trial.
Kurland L; Hallberg P; Melhus H; Liljedahl U; Hashemi N; Syvänen AC; Lind L; Kahan T
Am J Hypertens; 2008 Jul; 21(7):836-9. PubMed ID: 18464745
[TBL] [Abstract][Full Text] [Related]
7. Association of cigarette smoking with steady-state plasma concentration of irbesartan in male Chinese with hypertension.
Zhang S; Liu P; Jiang S; Hong X; Xing H; Xu X
Methods Find Exp Clin Pharmacol; 2005 Apr; 27(3):173-8. PubMed ID: 15834449
[TBL] [Abstract][Full Text] [Related]
8. Arg347Cys polymorphism of alpha1A-adrenoceptor gene is associated with blood pressure response to nifedipine GITS in Chinese hypertensive patients.
Zhang Y; Hong X; Liu H; Huo Y; Xu X
J Hum Genet; 2009 Jun; 54(6):360-4. PubMed ID: 19444285
[TBL] [Abstract][Full Text] [Related]
9. Effects of protein coding polymorphisms in the kallikrein 1 gene on baseline blood pressure and antihypertensive response to irbesartan in Chinese hypertensive patients.
Jiang S; Hsu YH; Venners SA; Zhang Y; Xing H; Wang X; Xu X
J Hum Hypertens; 2011 May; 25(5):327-33. PubMed ID: 20613781
[TBL] [Abstract][Full Text] [Related]
10. A home blood pressure monitoring study comparing the antihypertensive efficacy of two angiotensin II receptor antagonist fixed combinations.
Bobrie G; Delonca J; Moulin C; Giacomino A; Postel-Vinay N; Asmar R;
Am J Hypertens; 2005 Nov; 18(11):1482-8. PubMed ID: 16280286
[TBL] [Abstract][Full Text] [Related]
11. The pharmacokinetics of irbesartan in hypertensive children and adolescents.
Sakarcan A; Tenney F; Wilson JT; Stewart JJ; Adcock KG; Wells TG; Vachharajani NN; Hadjilambris OW; Slugg P; Ford NF; Marino MR
J Clin Pharmacol; 2001 Jul; 41(7):742-9. PubMed ID: 11452706
[TBL] [Abstract][Full Text] [Related]
12. Aldosterone synthase (CYP11B2) -344 C/T polymorphism is related to antihypertensive response: result from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation versus Atenolol (SILVHIA) trial.
Kurland L; Melhus H; Karlsson J; Kahan T; Malmqvist K; Ohman P; Nyström F; Hägg A; Lind L
Am J Hypertens; 2002 May; 15(5):389-93. PubMed ID: 12022239
[TBL] [Abstract][Full Text] [Related]
13. [Comparison of the antihypertensive activity of fosinopril and irbesartan].
Angulo E; Robles NR; Grois J; Barquero A; Pérez Miranda M
An Med Interna; 2002 Nov; 19(11):571-5. PubMed ID: 12522893
[TBL] [Abstract][Full Text] [Related]
14. Renin-angiotensin-aldosterone system gene polymorphisms and antihypertensive response to irbesartan in Chinese hypertensives.
Liu H; Zhang S; Jiang S; Mao G; Hong X; Yu Y; Zhang Y; Tang G; Xing H; Xu X
Methods Find Exp Clin Pharmacol; 2008 May; 30(4):307-12. PubMed ID: 18773126
[TBL] [Abstract][Full Text] [Related]
15. Aliskiren, a novel orally effective renin inhibitor, provides dose-dependent antihypertensive efficacy and placebo-like tolerability in hypertensive patients.
Gradman AH; Schmieder RE; Lins RL; Nussberger J; Chiang Y; Bedigian MP
Circulation; 2005 Mar; 111(8):1012-8. PubMed ID: 15723979
[TBL] [Abstract][Full Text] [Related]
16. BP goal achievement in patients with uncontrolled hypertension : results of the treat-to-target post-marketing survey with irbesartan.
Schrader J; Bramlage P; Lüders S; Thoenes M; Schirmer A; Paar DW
Clin Drug Investig; 2007; 27(11):783-96. PubMed ID: 17914897
[TBL] [Abstract][Full Text] [Related]
17. Comparison of fixed-dose combinations of telmisartan/hydrochlorothiazide 40/12.5 mg and 80/12.5 mg and a fixed-dose combination of losartan/hydrochlorothiazide 50/12.5 mg in mild to moderate essential hypertension: pooled analysis of two multicenter, prospective, randomized, open-label, blinded-end point (PROBE) trials.
Lacourcière Y; Neutel JM; Schumacher H
Clin Ther; 2005 Nov; 27(11):1795-805. PubMed ID: 16368450
[TBL] [Abstract][Full Text] [Related]
18. Comparison of monotherapy with irbesartan 150 mg or amlodipine 5 mg for treatment of mild-to-moderate hypertension.
Neutel JM; Germino FW; Smith D
J Renin Angiotensin Aldosterone Syst; 2005 Sep; 6(2):84-9. PubMed ID: 16470487
[TBL] [Abstract][Full Text] [Related]
19. Metabolic and antihypertensive effects of moxonidine and moxonidine plus irbesartan in patients with type 2 diabetes mellitus and mild hypertension: a sequential, randomized, double-blind clinical trial.
Derosa G; Cicero AF; D'Angelo A; Fogari E; Salvadeo S; Gravina A; Ferrari I; Fassi R; Fogari R
Clin Ther; 2007 Apr; 29(4):602-10. PubMed ID: 17617283
[TBL] [Abstract][Full Text] [Related]
20. Effect of three months' treatment with irbesartan on blood and pulse pressure of hypertensive type 2 diabetic patients: open, observational study in 31,793 patients.
Strutz F; Bramlage P; Paar WD
Curr Med Res Opin; 2005 Sep; 21(9):1433-40. PubMed ID: 16197662
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
